Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2001

View Archived Issues

Vaccine for group A Streptococcus enters phase I/II in Canada

OGS reports substantial progress on all fronts during past year

Unigene reports oral delivery of PTH analog

Lynx Therapeutics and UroGene collaborate to identify anticancer genes

MGI Pharma commences new phase II trial of irofulven for treatment of ovarian cancer

Immunex reports data from two of three Nuvance phase II studies; third study continues

FDA approves Cygnus' glucose monitoring device

Iomed and Santen to develop treatment of posterior eye diseases

Positive phase III results reported for Enbrel in psoriatic arthritic patients

IDDS commences phase I/II trial of nasal ketamine for treatment of acute pain

Novel APP inhibitor shows kinin-dependent reduction in MI size

Noven's Estradot transdermal HRT approved in the Netherlands

DuPont Pharmaceuticals' roxifiban study amended

Several agents compared in structural reorganization of myocardial collagen post-MI

Adenosine A2A receptor agonist reduces infarct size in dog model

VPI fails to show better cardioprotection than ACE inhibitor in MI rat model

Tetrahydrobiopterin shows cardioprotective activity in experimental model

New data presented for Japan Tobacco's novel cardioprotective drug

Dainippon's new elastase inhibitor offers potential for critical care of ARDS and septic shock

New polypeptides useful as vaccines for bacterial infections

Abbott discovers new potassium channel openers useful for bladder overactivity, etc.

Novartis describes new series of purine derivatives for inflammatory or allergic conditions

New compounds useful for CNS disorders patented by Ortho-McNeil

New azaindolinone derivatives patented by Zenyaku Kogyo

Multivalent compounds claimed by P&G useful for hair loss, etc.

Novel cPLA2 inhibitors with antiinflammatory activity reported by Nippon Soda

AVI BioPharma's antisense agent slows tumor growth in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld Science
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...